EGFR and non-small cell lung carcinoma: Further, we demonstrate that combination therapy of ATV and Gefitinib reverses induced EGFR-TKI resistant EGFR mutated (PC-9GR and H1975) but not in native EGFR-TKI resistant EGFR wild-type NSCLC cells (H1703).